MPM1 Antibody

What is the MPM-2 antibody and what epitopes does it recognize?

MPM-2 is a mouse monoclonal antibody that specifically recognizes phosphorylated epitopes (primarily LTPLK motifs) on a diverse group of proteins that are phosphorylated during mitosis. It serves as a valuable marker for detecting mitotic phosphoproteins in various experimental applications. The antibody reacts with human samples and has been validated for multiple techniques including immunocytochemistry, immunoprecipitation, ELISA, Western blotting, and flow cytometry . Unlike antibodies targeting single proteins, MPM-2 recognizes a phosphorylation-dependent epitope present on numerous proteins that appear specifically during mitosis, making it an excellent marker for cells undergoing division.

How does MPM-2 differ from other mitotic marker antibodies like anti-NPM1?

While MPM-2 recognizes a broad spectrum of phosphorylated mitotic proteins, antibodies like anti-NPM1 target specific individual proteins involved in cell division. NPM1 antibodies detect Nucleophosmin 1 (also known as B23), a 38 kDa nucleolar protein with functions in centrosome duplication and chromatin remodeling . NPM1 antibodies are used to study specific protein functions and mutations, whereas MPM-2 provides a broader view of the mitotic phosphorylation landscape. Unlike MPM-2, which shows diffuse cellular staining patterns during mitosis, NPM1 antibodies typically show nucleolar localization in interphase cells and dispersed patterns during mitosis when the nucleolus disassembles .

What are the optimal applications for MPM-2 antibody in cell cycle research?

MPM-2 antibody is particularly valuable for:

• Flow cytometric analysis of mitotic cell populations

• Immunofluorescence studies to visualize mitotic cells in tissue sections or cell cultures

• Immunoprecipitation of mitotic phosphoproteins for further characterization

• Western blot analysis of cell cycle-dependent protein phosphorylation

The antibody has been cited in numerous publications and validated for applications including ICC, IP, ELISA, WB, IHC-P, ICC/IF, and intracellular flow cytometry . For optimal results in immunofluorescence applications, MPM-2 antibody can be paired with DNA stains to correlate phosphoprotein signals with chromatin condensation patterns characteristic of different mitotic stages.

What are the recommended protocols for using MPM-2 in immunofluorescence studies?

For optimal immunofluorescence results with MPM-2:

• Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilize with 0.1% Triton X-100 for 10 minutes

• Block with 3% BSA in PBS for 1 hour

• Incubate with MPM-2 antibody (typically at 5-25 μg/mL concentration) for 3 hours at room temperature or overnight at 4°C

• Wash 3x with PBS

• Incubate with fluorophore-conjugated secondary antibody (similar to NorthernLights™ 557-conjugated Anti-Mouse IgG) for 1 hour

• Counterstain with DAPI to visualize DNA

• Mount and image using a fluorescence microscope

This protocol has been validated for detecting phosphorylated mitotic proteins in various cell types . Specific staining should be localized according to the mitotic phase, with patterns changing from nuclear to pan-cellular as cells progress through mitosis.

How should researchers optimize Western blotting conditions for MPM-2 antibody?

For Western blot optimization with MPM-2:

• Prepare lysates from asynchronous and mitotically enriched cell populations (e.g., using nocodazole treatment)

• Use phosphatase inhibitors in lysis buffer to preserve phosphoepitopes

• Load 20-30 μg total protein per lane

• Transfer to PVDF membrane (preferred over nitrocellulose for phosphoproteins)

• Block with 5% BSA in TBST (not milk, which contains phosphatases)

• Dilute MPM-2 antibody at 1:1000 in blocking buffer

• Incubate overnight at 4°C

• Use HRP-conjugated secondary antibody and ECL detection

Expected results should show multiple bands in mitotic samples that are absent or reduced in interphase cells. For comparison, when using specific antibodies like anti-NPM1, you would expect a single band at approximately 38 kDa , whereas MPM-2 will recognize multiple phosphoproteins of various molecular weights.

What controls should be included when using MPM-2 antibody in experiments?

Essential controls for MPM-2 experiments include:

Additionally, for cell cycle studies, co-staining with cell cycle markers (cyclins, pH3) or DNA content analysis can validate the specificity of MPM-2 for mitotic cells . For experiments requiring absolute specificity, phospho-specific antibodies targeting individual mitotic proteins (like NPM1) may provide complementary data .

How can MPM-2, when used alongside NPM1 antibodies, provide insights into centrosome duplication defects?

Combining MPM-2 and NPM1 antibodies can reveal intricate details about centrosome duplication abnormalities:

NPM1 normally associates with unduplicated centrosomes and, after phosphorylation at Thr199, dissociates to allow centrosome duplication . By using MPM-2 to identify mitotic cells and anti-NPM1 to track nucleophosmin localization, researchers can:

• Detect temporal relationships between mitotic phosphorylation events and NPM1 redistribution

• Identify defects in centrosome duplication mechanisms that may lead to genomic instability

• Correlate aberrant NPM1 phosphorylation with centrosome amplification in cancer cells

• Quantify the proportion of cells with abnormal centrosome numbers across the cell cycle

This dual-staining approach provides mechanistic insights linking phosphorylation events detected by MPM-2 with the functional consequences of NPM1 dynamics. In normal cells, NPM1 dissociates from centrosomes during mitotic entry (when MPM-2 epitopes appear), while in cells with centrosome duplication defects, this coordinated timing may be disrupted .

What are the methodological considerations when using MPM-2 to study phosphorylation dynamics during mitotic progression?

To effectively study phosphorylation dynamics with MPM-2:

• Cell Synchronization: Implement multiple synchronization methods (thymidine block, nocodazole, CDK1 inhibitors) to capture cells at specific mitotic stages

• Time-course Analysis: Collect samples at short intervals (5-10 minutes) following release from mitotic arrest

• Quantitative Imaging: Use automated image analysis to quantify MPM-2 signal intensity changes

• Multi-parameter Flow Cytometry: Combine MPM-2 with DNA content analysis and additional markers (Cyclin B1, pH3) for precise cell cycle positioning

• Phosphatase Inhibitor Optimization: Test different inhibitor cocktails to preserve labile phosphoepitopes

When studying dynamic processes, it's essential to validate findings using multiple techniques. For example, while immunofluorescence provides spatial information about MPM-2 reactivity, Western blotting can reveal the temporal appearance of specific phosphoproteins, and flow cytometry can quantify population-level changes .

How can researchers resolve contradictory results between MPM-2 staining patterns and specific mitotic protein markers?

When MPM-2 staining conflicts with other mitotic markers, consider these methodological approaches:

• Epitope Masking: Some phosphoepitopes may be masked by protein-protein interactions. Try multiple fixation protocols (methanol vs. paraformaldehyde) and antigen retrieval methods.

• Phosphatase Activity: Endogenous phosphatases may dephosphorylate MPM-2 epitopes during sample preparation. Ensure phosphatase inhibitors are fresh and used at appropriate concentrations.

• Kinase Inhibition: If cells were treated with kinases inhibitors (research compounds or drugs), certain MPM-2 epitopes may not be phosphorylated despite cells being in mitosis.

• Antibody Cross-Reactivity: Verify specificity using phosphopeptide competition assays or phosphatase-treated controls.

• Cell Type Variations: Different cell types may exhibit distinct patterns of mitotic phosphorylation. Compare your results across multiple cell lines.

For definitive analysis, combine MPM-2 with antibodies targeting specific mitotic proteins like NPM1 and additional markers such as phospho-histone H3 to establish precise mitotic timing.

How do sample preparation methods affect MPM-2 epitope detection compared to other mitotic markers?

Sample preparation significantly impacts MPM-2 epitope detection:

Critical considerations include:

• Phosphoepitopes recognized by MPM-2 are more labile than structural epitopes detected by antibodies like anti-NPM1

• Rapid fixation post-collection is essential to prevent phosphatase-mediated epitope loss

• Use of phosphatase inhibitor cocktails (including sodium fluoride, sodium orthovanadate, and β-glycerophosphate) is crucial for preserving MPM-2 reactivity

• Some fixatives may cause epitope masking that can be reversed with appropriate antigen retrieval methods

What are the potential causes and solutions for high background when using MPM-2 antibody?

High background with MPM-2 can arise from several sources:

• Non-specific antibody binding

  • Solution: Optimize blocking (try 5% BSA instead of serum) and increase wash duration/stringency

• Incomplete fixation

  • Solution: Ensure proper fixation time and concentration (4% PFA for 15 minutes)

• Over-detection in Western blots

  • Solution: Reduce antibody concentration or exposure time; compare with NPM1 antibody (which typically gives cleaner results) as a reference

• Cell stress inducing off-target phosphorylation

  • Solution: Minimize manipulation time, maintain appropriate temperature, and verify cell health

• Secondary antibody cross-reactivity

  • Solution: Use highly cross-adsorbed secondary antibodies and include secondary-only controls

For multi-color experiments, sequential antibody incubation rather than cocktail applications can reduce background, and inclusion of specific phosphatase inhibitors is essential for maintaining signal-to-noise ratio when detecting phosphoepitopes .

How should researchers quantify and interpret changes in MPM-2 signal intensity during cell cycle studies?

For robust quantification of MPM-2 signals:

• Flow Cytometry Analysis:

  • Plot MPM-2 intensity against DNA content to identify mitotic populations

  • Set thresholds using positive controls (nocodazole-arrested cells)

  • Calculate percentage of MPM-2-positive cells in each sample

  • Perform statistical analysis across replicate experiments

• Immunofluorescence Quantification:

  • Capture images using identical exposure settings across all samples

  • Measure nuclear/cellular intensity using image analysis software

  • Normalize to DAPI signal to account for chromatin condensation

  • Classify cells into mitotic phases based on chromatin morphology

  • Generate box plots showing MPM-2 intensity distribution by phase

• Western Blot Densitometry:

  • Measure intensity of major MPM-2-reactive bands

  • Normalize to loading controls (avoiding cell cycle-regulated proteins)

  • Create time-course profiles of phosphorylation changes

For cell cycle checkpoint studies, compare MPM-2 patterns with cell cycle-specific markers like cyclin B1 or phospho-histone H3. Unlike single-protein antibodies like NPM1 , MPM-2 signal represents a composite of multiple phosphorylation events, requiring careful interpretation in the context of specific experimental perturbations .

How do mutations in mitotic proteins like NPM1 affect their detection by phospho-specific antibodies?

Mutations in mitotic proteins can significantly alter antibody detection patterns:

For NPM1, mutations in the C-terminus (common in acute myeloid leukemia) disrupt nucleolar localization, causing mislocalization to the cytoplasm . This cytoplasmic form, referred to as NPM1c, is exclusive to myeloid malignancies .

When studying mutated proteins:

• Use multiple antibodies targeting different epitopes (N-terminal vs. C-terminal)

• Compare phospho-specific antibodies with total protein antibodies

• Employ mutation-specific antibodies when available, such as NPM1 C Mutant Specific antibody

• Consider how mutations might alter phosphorylation sites recognized by MPM-2

• Validate findings with recombinant protein controls (wild-type vs. mutant)

NPM1 mutations are heterozygous and function in a dominant negative fashion by dimerizing with wild-type NPM1 and recruiting it to the cytoplasm . This creates complex detection patterns requiring careful antibody selection and validation. When designing experiments involving mutated mitotic proteins, consider how mutations might affect both protein localization and phosphorylation status .

How are advanced imaging techniques enhancing the utility of MPM-2 and related antibodies in mitosis research?

Recent technological advances have expanded MPM-2 applications:

• Super-resolution Microscopy: Techniques like STORM and STED have revealed previously undetectable spatial relationships between MPM-2-reactive proteins and other mitotic structures, overcoming the diffraction limit of conventional microscopy.

• Live-cell Imaging: Development of cell-permeable phospho-specific probes based on MPM-2 epitope recognition allows real-time visualization of mitotic phosphorylation events.

• Multiplexed Imaging: Methods like Imaging Mass Cytometry and CODEX enable simultaneous detection of dozens of markers, allowing researchers to correlate MPM-2 signals with numerous other proteins.

• Correlative Light and Electron Microscopy (CLEM): This technique permits direct correlation between MPM-2 immunofluorescence and ultrastructural features of mitotic cells.

• Automated High-Content Screening: Machine learning algorithms can now classify mitotic stages based on MPM-2 staining patterns, enabling large-scale phenotypic screens.

When implementing these advanced techniques, researchers should validate findings using conventional methods, as each approach has distinct sensitivity thresholds and potential artifacts .

What emerging applications combine MPM-2 with proteomics or genomic approaches for comprehensive mitotic studies?

Cutting-edge integrated approaches include:

• Phosphoproteomics:

  • MPM-2 immunoprecipitation coupled with mass spectrometry identifies the complete repertoire of proteins containing the phosphoepitope

  • Comparison between normal and cancer cells reveals altered mitotic phosphorylation networks

• ChIP-seq with NPM1 and other mitotic protein antibodies:

  • NPM1 antibodies can be used in chromatin immunoprecipitation followed by sequencing to map genomic binding sites

  • Correlation with MPM-2 reactivity reveals phosphorylation-dependent chromatin associations

• Proximity Labeling:

  • BioID or APEX2 fusions to mitotic proteins identified by MPM-2 map their interaction networks during mitosis

  • Temporal changes in these networks reveal regulatory mechanisms

• Single-cell Multi-omics:

  • Combined analysis of phosphoproteome and transcriptome in single cells sorted based on MPM-2 reactivity

  • Reveals heterogeneity in mitotic progression within seemingly homogeneous populations

These integrated approaches provide systems-level insights into mitotic regulation, connecting phosphorylation events detected by MPM-2 with broader cellular processes and specific proteins like NPM1 .

What best practices should researchers follow when incorporating MPM-2 and related antibodies into mitosis studies?

To maximize the scientific value of experiments using mitotic protein antibodies:

• Validation: Always validate antibody specificity using appropriate positive and negative controls

• Multiple Methods: Combine at least two independent techniques (e.g., immunofluorescence and Western blotting)

• Quantification: Implement rigorous quantification methods with appropriate statistical analysis

• Complementary Markers: Use MPM-2 in conjunction with specific mitotic protein antibodies like NPM1 for comprehensive analysis

• Time-course Studies: Examine dynamic changes rather than single time points

• Pharmacological Controls: Include kinase and phosphatase inhibitors to validate phospho-specificity

• Cell Synchronization: Employ multiple synchronization methods to avoid method-specific artifacts

• Reproducibility: Ensure experimental conditions are precisely documented and reproducible

By adhering to these practices, researchers can generate robust and meaningful data that advances our understanding of mitotic regulation and its dysregulation in disease states.

How should researchers interpret MPM-2 results in the context of cancer research and potential therapeutic applications?

When applying MPM-2 in cancer research contexts:

• Diagnostic Applications: Compare MPM-2 staining patterns between normal and malignant tissues to identify aberrant mitotic signaling

• Therapeutic Response Monitoring: Use MPM-2 to assess how cancer cells respond to anti-mitotic drugs by quantifying changes in mitotic phosphorylation profiles

• Resistance Mechanisms: Investigate whether altered MPM-2 reactivity correlates with resistance to kinase inhibitors or other targeted therapies

• Biomarker Development: Evaluate specific MPM-2-reactive proteins as potential predictive biomarkers for treatment response

• Complement with Mutation Analysis: For comprehensive understanding, combine MPM-2 studies with analysis of mutations in mitotic regulators (like NPM1 mutations in AML)